Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

United Therapeutics Co. has a 52-week low of $221.53 and a 52-week high of $417.82. The stock has a market cap of $14.28 billion, a price-to-earnings ratio of 13.96, a PEG ratio of 0.97 and a beta ...

Implementing the ventilator-associated events (VAE) prevention protocol at Community Health Network has yielded remarkable ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP – Free Report) in a research report released on Thursday. The firm issued a buy rating on the biotechnology company’s ...

Fintel reports that on March 11, 2025, Jones Trading initiated coverage of Serina Therapeutics (NYSEAM:SER) with a Buy ...

Knight Therapeutics Inc. (TSX: GUD) ("Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2024 financial results on Thursday, March 20, ...

MONTREAL, March 11, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that it has entered into a ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S.